FDA chief counsel resigns

Drug Store News, Dec 13, 2004

WASHINGTON -- Daniel Troy resigned Nov. 28 as chief counsel for the Food and Drug Division of the Food and Drug Administration s Office of the General Counsel. Troy has served as the FDA's senior legal advisor since his appointment in August 2001.

Acting FDA Commissioner Dr. Lester Crawford praised the Bush appointee for his "tireless dedication" in areas like counter-terrorism and generic-drug reforms. "Shortly after Dan's arrival, he faced a major challenge, assisting the agency in addressing the myriad public health dimensions of the terrorist attacks of Sept. 11, 2001," Crawford said. "Thereafter, he provided excellent legal support to the agency as we responded to the anthrax attacks and reoriented the agency to its new counterterrorism responsibilities.

"Dan's legal acumen has equally benefited FDA's programs aimed at carrying out the agency's traditional public health mission, including the notable accomplishment of the major package of reforms to the Hatch-Waxman amendments to the Federal Food, Drug and Cosmetic Act, which are estimated to save drug consumers $35 billion over 10 years," Crawford added.